{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:38:52Z","timestamp":1784299132824,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Contrast-induced nephropathy (CIN) is a common complication after percutaneous coronary intervention (PCI). There is conflicting evidence regarding efficacy of nicorandil in CIN prevention. With respect to ranolazine, there is physiological possibility as well as data in animal study regarding its protective effect against CIN; there is, however, no human data till date.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim and objectives<\/jats:title>\n            <jats:p>To assess the efficacy of nicorandil and ranolazine in preventing CIN. The secondary endpoint was to measure difference in postprocedure acute kidney injury (AKI) incidence across groups. Also, patients were followed up till 6 months for major adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material and methods<\/jats:title>\n            <jats:p>This single-center randomized controlled study included 315 patients of coronary artery disease with mild-to-moderate renal dysfunction undergoing elective PCI. Eligible patients were assigned to either nicorandil (n\u2005=\u2005105), ranolazine (n\u2005=\u2005105) or control group (n\u2005=\u2005105) in 1\u2005:\u20051\u2005:\u20051 ratio by block randomization. All enrolled patients were given intravenous sodium chloride at rate of 1.0\u2005mL\/kg\/h (0.5\u2005mL\/kg\/h for patients with left ventricular ejection fraction &lt;45%) from 6\u2005h before procedure till 12\u2005h after procedure. Iso-osmolar contrast agent (iodixanol) was used for all patients. In addition to hydration, patients in nicorandil group received oral nicorandil (10\u2005mg, 3 times\/d) and those in ranolazine group received oral ranolazine (1000\u2005mg, 2 times\/d) 1 day before procedure and for 2 days after PCI. Patients in control group received only hydration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Total number of CIN was 34 (10.7%), which included 19 (18.1%) in control, 8 (7.6%) in nicorandil and 7 (6.6%) in ranolazine group. There was significant association of CIN reduction across groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.012). On pairwise comparison also, there was significant benefit across control and ranolazine as well as control and nicorandil (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.025). There was numerically higher incidence of AKI in controls; the difference, however, did not reach statistical significance after applying Bonferroni correction (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.044). Over 6-month follow-up, adverse events were similar across groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>While this study adds to existing literature that supports role for nicorandil in CIN prevention, the efficacy of ranolazine in protecting against CIN has been demonstrated in humans for the first time.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001347","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T07:00:59Z","timestamp":1709017259000},"page":"186-192","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial"],"prefix":"10.1097","volume":"35","author":[{"given":"Jamal","family":"Yusuf","sequence":"first","affiliation":[{"name":"Department of Cardiology, Maulana Azad Medical College and GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyan","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maulana Azad Medical College and GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safal","family":"Safal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maulana Azad Medical College and GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maulana Azad Medical College and GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saibal","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maulana Azad Medical College and GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.05.099","article-title":"Contrast-induced acute kidney injury.","volume":"68","author":"McCullough","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1136\/hrt.2010.218677","article-title":"Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention.","volume":"97","author":"Wi","year":"2011","journal-title":"Heart"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/eurheartj\/ehr494","article-title":"Contrast-induced kidney injury: mechanisms, risk factors, and prevention.","volume":"33","author":"Seeliger","year":"2012","journal-title":"Eur Heart J"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.ajkd.2016.07.033","article-title":"Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: a systematic review and Bayesian network meta-analysis.","volume":"69","author":"Su","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ehj.2003.11.011","article-title":"Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.","volume":"25","author":"Goldenberg","year":"2004","journal-title":"Eur Heart J"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-148-4-200802190-00007","article-title":"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.","volume":"148","author":"Kelly","year":"2008","journal-title":"Ann Intern Med"},{"key":"R7-20250729","first-page":"1","article-title":"The prevention of acute kidney injury: an in-depth narrative review part 2: drugs in the prevention of acute kidney injury.","volume":"2","author":"Lameire","year":"2009","journal-title":"NDT Plus"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12872-019-1071-x","article-title":"Meta-analysis of nicorandil effectiveness on myocardial protection after percutaneous coronary intervention.","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijcard.2015.05.078","article-title":"Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.","volume":"195","author":"Nawa","year":"2015","journal-title":"Int J Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s00380-016-0809-y","article-title":"Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.","volume":"31","author":"Fan","year":"2016","journal-title":"Heart Vessels"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5603\/CJ.a2017.0028","article-title":"Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: a prospective randomized controlled trial.","volume":"24","author":"Iranirad","year":"2017","journal-title":"Cardiol J"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3349\/ymj.2013.54.4.957","article-title":"Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study).","volume":"54","author":"Ko","year":"2013","journal-title":"Yonsei Med J"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrd2069","article-title":"Ranolazine.","volume":"5","author":"Abrams","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12020-017-1243-3","article-title":"Ranolazine promotes muscle differentiation and reduces oxidative stress in C2C12 skeletal muscle cells.","volume":"58","author":"Terruzzi","year":"2017","journal-title":"Endocrine"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1054\/jcaf.2002.129232","article-title":"Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.","volume":"8","author":"Sabbah","year":"2002","journal-title":"J Card Fail"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1139\/cjpp-2018-0571","article-title":"Cardioprotective effect of ranolazine in nondiabetic and diabetic male rats subjected to isoprenaline-induced acute myocardial infarction involves modulation of AMPK and inhibition of apoptosis.","volume":"97","author":"Tawfik","year":"2019","journal-title":"Can J Physiol Pharmacol"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lfs.2016.05.026","article-title":"Ranolazine improves oxidative stress and mitochondrial function in the atrium of acetylcholine-CaCl2 induced atrial fibrillation rats.","volume":"156","author":"Zou","year":"2016","journal-title":"Life Sci"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21608\/muj.2020.25106.1007","article-title":"The possible antidiabetic effects of ranolazine versus gliclazide in HFD\/STZ-induced type 2 diabetes in male albino rats.","volume":"1","author":"Elkholy","year":"2020","journal-title":"Med Updates"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"118920","DOI":"10.1016\/j.lfs.2020.118920","article-title":"Ranolazine alleviates contrast-associated acute kidney injury through modulation of calcium independent oxidative stress and apoptosis.","volume":"267","author":"Ma","year":"2021","journal-title":"Life Sci"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s003300050894","article-title":"Contrast-media-induced nephrotoxicity: a consensus report. Contrast media safety committee, European Society of Urogenital Radiology (ESUR).","volume":"9","author":"Morcos","year":"1999","journal-title":"Eur Radiol"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ki.5000368","article-title":"Contrast-induced nephropathy: definition, epidemiology, and patients at risk.","volume":"69","author":"Mehran","year":"2006","journal-title":"Kidney Int Suppl"},{"key":"R23-20250729","first-page":"6988","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Section 4: contrast induced AKI.","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/opo.12131","article-title":"When to use the Bonferroni correction.","volume":"34","author":"Armstrong","year":"2014","journal-title":"Ophthalmic Physiol Opt"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/01.CIR.83.2.484","article-title":"In-hospital and 1-year mortality in 1,524 women after myocardial infarction: comparison with 4,315 men.","volume":"83","author":"Greenland","year":"1991","journal-title":"Circulation"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.jcin.2019.04.055","article-title":"Procedural strategies to reduce the incidence of contrast-induced acute kidney injury during percutaneous coronary intervention.","volume":"12","author":"Almendarez","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MNH.0000000000000389","article-title":"Maximum allowable contrast dose and prevention of acute kidney injury following cardiovascular procedures.","volume":"27","author":"Aoun","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00278485","article-title":"Pharmacokinetics of nicorandil in patients with normal and impaired renal function.","volume":"42","author":"Molinaro","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"R29-20250729","first-page":"830","article-title":"Pharmacokinetics of iopamidol in adults with renal failure.","volume":"40","author":"Corradi","year":"1990","journal-title":"Arzneimittelforschung"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/0003319717732237","article-title":"Effect of nicorandil administration on preventing contrast-induced nephropathy: a meta-analysis.","volume":"69","author":"Zhan","year":"2018","journal-title":"Angiology"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:02:55Z","timestamp":1753812175000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001347","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}